Pfizer Inc. (NYSE: PFE) beats Q2-2026 adjusted Non-GAAP EPS consensus of approx. $0.68 per share (August 4, 2026)
Hit
✦ AI-generated prediction
Published on 17. July 2026
·
Predicted for 4. August 2026
·
Based on: Historical Cycle
Pfizer reports Q2-2026 results on August 4, 2026; analyst consensus stands at adjusted Non-GAAP EPS of approx. $0.68 (-12.8% YoY, prior year $0.78). Pfizer has actively restructured its portfolio post-COVID revenue decline — the Seagen acquisition and further oncology assets are expected to increasingly contribute to earnings from 2026. In the last four quarters Pfizer beat EPS expectations three times. Positive catalysts: RSV vaccine recovery (Abrysvo), gradual Paxlovid revenue return in budget-adjusted markets, and cost-reduction program on track. No Polymarket/Kalshi market available for this event.
Data basis for this prediction
- Nasdaq/Pfizer IR: Q2-2026-Bericht 4. August 2026 vor Börseneröffnung bestätigt
- Yahoo Finance: Konsens Non-GAAP EPS PFE Q2 2026 ~0,68 USD (-12,8 % YoY, Stand Juli 2026)
- Pfizer IR: Beat-Bilanz letzte 4 Quartale – 3 von 4 Quartalen EPS-Konsens übertroffen
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Hit
Pfizer meldete am 4. August 2026 einen bereinigten Non-GAAP-EPS von 0,77 USD für Q2 2026 – ein klarer Beat gegenüber dem Analystenkonsens von ca. 0,68 USD (Zacks). Das entspricht einer Übertreffung um 9 Cent bzw. ~13 %. Treiber waren Wachstum bei Eliquis, Padcev, der Vyndaqel-Familie und Lorbrena (überwiegend Seagen-Assets), die COVID-19-Rückgänge mehr als kompensierten. Pfizer hat damit laut eigenen Angaben den EPS-Konsens in allen zehn der letzten zehn Quartale übertroffen. Quellen: Yahoo Finance / Zacks ('PFE Q2 Earnings Top, 2026 Sales View Tweaked'), Seeking Alpha ('Pfizer tops Q2 expectations'), CNBC Q2-2026-Bericht.
📈 Economy
✦ AI
The S&P 500 dropped 4.36% on 5 November 2026 to 7,353.73 — its steepest one-day fall since April 2025 — triggered by an AI-chip selloff that wiped out the post-midterm rally (4 November: +1.72% to 7,698.80). Closing above 7,500 by 13 November requires a +2.0% recovery over 6 trading sessions. Goldman Sachs, Morgan Stanley and JPMorgan maintain year-end targets of 7,400–8,100; S&P 500 EPS growth consensus for 2026 stands at +14% YoY. Downside risks: elevated Treasury yields, persistent AI capex uncertainty. No specific Polymarket/Kalshi market found for this level.
📈 Economy
✦ AI
The BLS releases October 2026 CPI on November 10, 2026 at 8:30 AM ET. Nowflation forecasts 3.82 percent YoY; the Cleveland Fed nowcasting model forecasts 3.74 percent — both clearly above the 3.7 percent threshold. The September 2026 prior reading was exactly 3.7 percent. Rising energy prices (Strait of Hormuz effectively closed since mid-October) and stable core inflation support a further uptick. An existing open platform prediction covers CPI >3.5%; this forecast raises the bar by 20 basis points. A miss would primarily require unexpected weakness in the energy component or food prices.
📈 Economy
✦ AI
Gold (XAU/USD) rose to $4,134.83 on 5 November 2026 — driven by the Democratic midterm sweep (higher fiscal spending expected) and persistent inflation pressure. Kalshi's Dec 31 settlement market shows ~32% probability for a close above $4,400 and ~43% for above $4,300. Reaching the $4,400 year-end target would require a further ~6.4% gain. Supporting factors: fiscal expansion, geopolitical risks, structurally high central bank demand; UBS forecasts $4,800, JPMorgan $6,000 at year-end. Headwind: hawkish Fed stance (Polymarket: 72.5% for a December rate hike to 4.00–4.25%). Prediction anchors on Kalshi's ~32% for >$4,400.